Durham-based Precision BioSciences has received IND clearance for PBGENE-HBV, making it the first investigational in vivo gene-editing therapy to...
YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...
Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...
Some of the best links we picked up around the internet
